Published in JAMA Pediatr on March 01, 2015
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet (2015) 0.94
The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax (2016) 0.78
Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children. J Int AIDS Soc (2015) 0.78
Intermittent Short Course Rifapentine-Isoniazid Combination for Preventing Tuberculosis in Children: Evidence based Medicine Viewpoint. Indian Pediatr (2015) 0.77
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS (2016) 0.77
Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia (Nathan) (2016) 0.77
Getting to Zero: Tuberculosis Elimination in California. Curr Epidemiol Rep (2016) 0.75
Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis (2017) 0.75
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
Diagnosis and management of pediatric tuberculosis in Canada. CMAJ (2017) 0.75
Twelve-dose drug regimen now also an option for preventing tuberculosis in children and adolescents. JAMA Pediatr (2015) 0.75
Tuberculosis in Children. Pediatr Clin North Am (2017) 0.75
Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One (2017) 0.75
Pediatric Multidrug Resistant Tuberculosis Clinical Trials: Challenges and Opportunities. Int J Infect Dis (2016) 0.75
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials (2003) 3.30
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuberc Lung Dis (2014) 2.08
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis (2005) 1.27
Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One (2010) 1.15
Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis (2009) 1.05
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis (2013) 0.97
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis (2005) 0.94
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis (2008) 0.93
Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb) (2015) 0.83
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis (2015) 0.83
Quality assurance in a large clinical trials consortium: the experience of the Tuberculosis Trials Consortium. Contemp Clin Trials (2006) 0.80
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Pharmacotherapy (2007) 0.78
Effect of improving the quality of radiographic interpretation on the ability to predict pulmonary tuberculosis relapse. Acad Radiol (2009) 0.75
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. Antimicrob Agents Chemother (2017) 0.75